Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up
- 1 January 2010
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 39 (1) , 12-18
Abstract
Objective: To investigate the 15-year outcome of patients with early rheumatoid arthritis (ERA) with respect to the continuity of treatment. Methods: We conducted a 15-year follow-up study of 87 patients with ERA treated since diagnosis with disease-modifying anti-rheumatic drugs (DMARDs) according to the ‘sawtooth’ strategy. The patients were divided into groups according to the continuity of treatment: (A) ‘continuous DMARDs’, (B) ‘discontinued and restarted DMARDs’, and (C) ‘permanently discontinued DMARDs’. The main outcome measurements included the Health Assessment Questionnaire (HAQ), the Larsen score, and clinical remission according to the American Rheumatism Association (ARA) criteria. Results: Seventy (80%) patients participated in the 15-year follow-up. DMARDs were discontinued in 20 (29%) patients due either to remission or to a symptom-free period of the disease. The disease flared up in nine (45%) of these patients, in some patients several years after the discontinuation. At the 15-year follow-up, 59 (84%) patients were on DMARDs; only three (4%) were using biologicals. Functional capacity remained good in all groups (mean HAQ score 0.52). The mean Larsen score was higher (54) in group A than in groups B (25) and C (12) (p =0.001). The remission rate was 64% in group C and considerably lower in groups A (6%) and B (0%) (p<0.001). Conclusions: Our results indicate that most of the patients with long-standing RA require continuous DMARD treatment. If the treatment is discontinued, patients should be followed-up closely and DMARDs readministered without delay if the disease flares up.Keywords
This publication has 33 references indexed in Scilit:
- Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)Annals of the Rheumatic Diseases, 2007
- Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDsNature Clinical Practice Rheumatology, 2007
- Long‐term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta‐analysisArthritis Care & Research, 2006
- Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuationAnnals of the Rheumatic Diseases, 1997
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- A COMPARISON OF DISABILITY MEASURED BY THE STANFORD HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY SCALES (HAQ) IN MALE AND FEMALE RHEUMATOID OUTPATIENTSRheumatology, 1991
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980